Needham & Company LLC Reaffirms “Buy” Rating for Adamas Pharmaceuticals, Inc. (ADMS)
Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS)‘s stock had its “buy” rating restated by analysts at Needham & Company LLC in a research note issued to investors on Sunday. They presently have a $38.00 target price on the specialty pharmaceutical company’s stock. Needham & Company LLC’s target price would suggest a potential upside of 76.50% from the stock’s current price.
A number of other research firms also recently commented on ADMS. BidaskClub upgraded Adamas Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, August 23rd. Mizuho reiterated a “buy” rating and issued a $26.00 price objective on shares of Adamas Pharmaceuticals in a report on Tuesday, September 5th. Piper Jaffray Companies reiterated an “overweight” rating and issued a $30.00 price objective on shares of Adamas Pharmaceuticals in a report on Friday, September 1st. They noted that the move was a valuation call. Noble Financial reiterated a “buy” rating on shares of Adamas Pharmaceuticals in a report on Wednesday, August 9th. Finally, Cowen and Company reiterated an “outperform” rating and issued a $45.00 price objective on shares of Adamas Pharmaceuticals in a report on Sunday, May 28th. Two analysts have rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $33.00.
Adamas Pharmaceuticals (NASDAQ:ADMS) opened at 21.53 on Friday. The stock’s market cap is $484.73 million. Adamas Pharmaceuticals has a 1-year low of $12.10 and a 1-year high of $22.58. The firm has a 50-day moving average price of $18.00 and a 200 day moving average price of $17.19.
Adamas Pharmaceuticals (NASDAQ:ADMS) last issued its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.93) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.81) by ($0.12). Adamas Pharmaceuticals had a negative return on equity of 52.91% and a negative net margin of 10,499.65%. The company had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.03 million. During the same quarter last year, the company earned ($0.78) EPS. Adamas Pharmaceuticals’s revenue for the quarter was down 90.9% compared to the same quarter last year. On average, equities research analysts anticipate that Adamas Pharmaceuticals will post ($3.79) EPS for the current fiscal year.
In related news, major shareholder Great Point Partners Llc sold 380,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 21st. The stock was sold at an average price of $17.08, for a total transaction of $6,490,400.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders have sold a total of 731,041 shares of company stock worth $12,476,149 in the last 90 days. 29.00% of the stock is currently owned by company insiders.
A number of institutional investors have recently bought and sold shares of the business. Tower Research Capital LLC TRC acquired a new stake in Adamas Pharmaceuticals during the 2nd quarter worth approximately $109,000. State Street Corp lifted its position in Adamas Pharmaceuticals by 9.1% during the 2nd quarter. State Street Corp now owns 285,359 shares of the specialty pharmaceutical company’s stock worth $4,990,000 after acquiring an additional 23,708 shares during the period. Bamco Inc. NY lifted its position in Adamas Pharmaceuticals by 45.5% during the 2nd quarter. Bamco Inc. NY now owns 103,200 shares of the specialty pharmaceutical company’s stock worth $1,805,000 after acquiring an additional 32,272 shares during the period. Dimensional Fund Advisors LP lifted its position in Adamas Pharmaceuticals by 11.9% during the 2nd quarter. Dimensional Fund Advisors LP now owns 140,481 shares of the specialty pharmaceutical company’s stock worth $2,457,000 after acquiring an additional 14,987 shares during the period. Finally, Virtu KCG Holdings LLC acquired a new stake in Adamas Pharmaceuticals during the 2nd quarter worth approximately $184,000. 69.24% of the stock is owned by institutional investors.
Adamas Pharmaceuticals Company Profile
Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.
Receive News & Ratings for Adamas Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.